Source: ExploreBit

Atem Capital: Amolyt Pharma raises USD 138M Series C funding round

Amolyt Pharma Lyon France based company specialized in developing therapeutic peptides for rare endocrine and related diseases raises USD 138M Series C funding The round co led by Sofinnova Partners

Read full article »
Atem Capital's Competitors | Atem Capital's News | Atem Capital's Financials
Stay up-to-date with the latest news on Atem Capital
Est. Annual Revenue
$5.0-25M
Est. Employees
1-25
Anton Gopka's photo - CEO of Atem Capital

CEO

Anton Gopka

CEO Approval Rating

85/100

Read more
Stay up-to-date with the latest news on Atem Capital